A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2018
Price : $35 *
At a glance
- Drugs MSB 0010445 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors EMD Serono
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 15 Apr 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015 as per ClinicalTrials.gov record.